Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.

Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

Open access

Abstract

Thal amyloid phase, which describes the pattern of progressive amyloid-β plaque deposition in Alzheimer's disease, was incorporated into the latest National Institute of Ageing - Alzheimer's Association neuropathologic assessment guidelines. Amyloid biomarkers (positron emission tomography and cerebrospinal fluid) were included in clinical diagnostic guidelines for Alzheimer's disease dementia published by the National Institute of Ageing - Alzheimer's Association and the International Work group. Our first goal was to evaluate the correspondence of Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy cohort. Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy. (11)C-Pittsburgh compound B studies from Mayo Clinic Rochester were available for 35 participants scanned within 2 years of death. Cortical (11)C-Pittsburgh compound B values were calculated as a standard uptake value ratio normalized to cerebellum grey/white matter. In the high likelihood Alzheimer's disease brain bank cohort (n = 1375), cases with lower Thal amyloid phases were older at death, had a lower Braak tangle stage, and were less frequently APOE-ε4 positive. Regression modelling in these Alzheimer's disease cases, showed that Braak tangle stage, but not Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examination score. In contrast, Thal amyloid phase, but not Braak tangle stage or cerebral amyloid angiopathy predicted (11)C-Pittsburgh compound B standard uptake value ratio. In the 35 cases with ante-mortem amyloid imaging, a transition between Thal amyloid phases 1 to 2 seemed to correspond to (11)C-Pittsburgh compound B standard uptake value ratio of 1.4, which when using our pipeline is the cut-off point for detection of clear amyloid-positivity regardless of clinical diagnosis. Alzheimer's disease cases who were older and were APOE-ε4 negative tended to have lower amyloid phases. Although Thal amyloid phase predicted clinical characteristics of Alzheimer's disease patients, the pre-mortem clinical status was driven by Braak tangle stage. Thal amyloid phase correlated best with (11)C-Pittsburgh compound B values, but not Braak tangle stage or cerebral amyloid angiopathy. The (11)C-Pittsburgh compound B cut-off point value of 1.4 was approximately equivalent to a Thal amyloid phase of 1-2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awv050

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Murray et al. examine the correspondence between Thal amyloid phase, tau pathology and clinical characteristics in a large Alzheimer’s disease autopsy series. They extrapolate their findings to an autopsy cohort for which Pittsburgh compound-B imaging data are available, and evaluate the neuropathological significance of a quantitative amyloid-β imaging cut-off point.
Graphical abstract Murray et al. examine the correspondence between Thal amyloid phase, tau pathology and clinical characteristics in a large Alzheimer’s disease autopsy series. They extrapolate their findings to an autopsy cohort for which Pittsburgh compound-B imaging data are available, and evaluate the neuropathological significance of a quantitative amyloid-β imaging cut-off point.CC BY-NC · PubMed Central
Figure 1 Stereotypic progression of plaques in Thal amyloid phase. Regional distribution of thioflavin-S plaque counts by Thal amyloid phase from the Mayo Clinic Jacksonville brain bank series (n = 3618). From left to right, three association cortices, two primary cortices, and three allocortical (hippocampal) regions are displayed. The 3D distribution plots of median thioflavin-S plaque counts across Thal phase 0–5 demonstrate the incremental involvement of subsequent regions. Note the striking difference between involvement of association cortices and allocortices throughout each phase. Senile plaque counts were maximally counted to 50 per 3 mm2 using a ×10 objective.
Figure 1 Stereotypic progression of plaques in Thal amyloid phase. Regional distribution of thioflavin-S plaque counts by Thal amyloid phase from the Mayo Clinic Jacksonville brain bank series (n = 3618). From left to right, three association cortices, two primary cortices, and three allocortical (hippocampal) regions are displayed. The 3D distribution plots of median thioflavin-S plaque counts across Thal phase 0–5 demonstrate the incremental involvement of subsequent regions. Note the striking difference between involvement of association cortices and allocortices throughout each phase. Senile plaque counts were maximally counted to 50 per 3 mm2 using a ×10 objective.CC BY-NC · PubMed Central
Figure 2 Proportion of Braak NFT stage by Thal amyloid phase in Mayo Clinic Jacksonville Brain Bank. The proportion of each Braak NFT stages from the total for each Thal amyloid phase (found above each bar), was plotted across Thal amyloid Phase 0–5. The proportion of cases with Braak ≥IV by Thal amyloid phase was: Phase 0 = 3%, Phase 1 = 8%, Phase 2 = 11%, Phase 3 = 24%, Phase 4 = 59%, and Phase 5 = 94%.
Figure 2 Proportion of Braak NFT stage by Thal amyloid phase in Mayo Clinic Jacksonville Brain Bank. The proportion of each Braak NFT stages from the total for each Thal amyloid phase (found above each bar), was plotted across Thal amyloid Phase 0–5. The proportion of cases with Braak ≥IV by Thal amyloid phase was: Phase 0 = 3%, Phase 1 = 8%, Phase 2 = 11%, Phase 3 = 24%, Phase 4 = 59%, and Phase 5 = 94%.CC BY-NC · PubMed Central
Figure 3 Comparison of 11C-PiB SUV ratio images across each Thal amyloid phase. The PiB-PET SUV ratio values can be found below each Thal amyloid phase. Representative axial, sagittal, and coronal slices from PiB-PET of six Mayo Clinic Rochester participants’ shows increasing PiB-positivity with each subsequent Thal amyloid phase. All example images are spatially and intensity normalized. The heat map index (left) shows the start of green at a SUV ratio level of 1.4, which is the cut-off point used to assess PiB-positivity. Of note, cerebellar PiB-PET uptake in Thal amyloid Phase 5 is not visible as this is the region used to normalize the scan. SUVR = SUV ratio.
Figure 3 Comparison of 11C-PiB SUV ratio images across each Thal amyloid phase. The PiB-PET SUV ratio values can be found below each Thal amyloid phase. Representative axial, sagittal, and coronal slices from PiB-PET of six Mayo Clinic Rochester participants’ shows increasing PiB-positivity with each subsequent Thal amyloid phase. All example images are spatially and intensity normalized. The heat map index (left) shows the start of green at a SUV ratio level of 1.4, which is the cut-off point used to assess PiB-positivity. Of note, cerebellar PiB-PET uptake in Thal amyloid Phase 5 is not visible as this is the region used to normalize the scan. SUVR = SUV ratio.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 1

  1. 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x

Cited by

See all 351

Metadata

Authors
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W.
Affiliations
  • Mayo Clinic (US)
  • University of Miami (US)
Corresponding author
Murray, Melissa E.
Venue
Brain
Published
2015-03-23
Volume
138
Issue
5
Pages
1370-1381
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2148457471
Cited by
324
References
72
Citations by year
2026: 9 · 2025: 18 · 2024: 22 · 2023: 15 · 2022: 18 · 2021: 32 · 2020: 38 · 2019: 41 · 2018: 34 · 2017: 36 · 2016: 35 · 2015: 25
FWCI
35.14
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • National Institute on Aging (R01AG040042, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
  • National Institute of Neurological Disorders and Stroke (P50NS072187)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, amyloid plaques, APOE ε4, cerebral amyloid angiopathy, thioflavin S staining, age of onset, disease duration, amyloid biomarkers
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Female, Humans, Male, Middle Aged, Thiazoles, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. https://app.cochat.ai/papers/10.1093/brain/awv050
The paper
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W. (2015). Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain. https://doi.org/10.1093/brain/awv050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.